• In late April 2026, Merit Medical Systems reported first-quarter 2026 results showing US$381.88 million in sales and US$41 million in net income, with both basic and diluted earnings per share from continuing operations rising versus a year earlier and adjusted earnings and margins coming in ahead of analyst expectations.
• At the same time, the company slightly raised its full-year 2026 revenue guidance to about US$1.62 billion and expanded its oncology platform through the Viewpoint Medical acquisition and new product launches, reinforcing management’s focus on higher-value therapeutic offerings despite tariff and OEM headwinds.
• We’ll now examine how this raised 2026 revenue outlook, underpinned by Viewpoint Medical’s oncology contribution, affects Merit’s broader investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical today, you need to believe it can keep shifting its mix toward higher value therapeutic platforms in oncology, cardiovascular and endoscopy, while managing tariffs, recalls and OEM volatility. The Q1 beat and slightly higher 2026 revenue outlook support that thesis but do not materially change the near term balance between the key catalyst of oncology expansion and the biggest risk from cost and reimbursement pressures, particularly around WRAPSODY and tariffs.

The Viewpoint Medical acquisition is most relevant here, because it directly underpins the higher 2026 revenue guidance and broadens Merit’s oncology footprint with the OneMark tissue localization system. That deal, together with the new Resilience esophageal stent, ties the updated outlook to concrete product platforms that could influence margins and growth, but it also raises the stakes if integration or product adoption falls short while tariff expenses stay elevated.

Yet even with these positives, investors should be aware of how tariff costs and WRAPSODY reimbursement timing could still...

Merit Medical Systems’ narrative projects $1.8 billion revenue and $197.1 million earnings by 2029.

Uncover how Merit Medical Systems' forecasts yield a $98.36 fair value, a 59% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue around US$1.8 billion and earnings of US$210 million by 2029, and they focus much more on how acquisitions like Viewpoint and ongoing tariff and logistics pressures might curb margin progress, so if you are weighing this latest guidance raise you should know their narrative could either soften or harden from here.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth just $87.21!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.